GB0523810D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB0523810D0
GB0523810D0 GBGB0523810.0A GB0523810A GB0523810D0 GB 0523810 D0 GB0523810 D0 GB 0523810D0 GB 0523810 A GB0523810 A GB 0523810A GB 0523810 D0 GB0523810 D0 GB 0523810D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0523810.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0523810.0A priority Critical patent/GB0523810D0/en
Publication of GB0523810D0 publication Critical patent/GB0523810D0/en
Priority to TW095142644A priority patent/TW200735875A/zh
Priority to EP10182729A priority patent/EP2283828A1/en
Priority to KR1020087013620A priority patent/KR20080070056A/ko
Priority to JP2008541808A priority patent/JP2009516726A/ja
Priority to BRPI0618906-7A priority patent/BRPI0618906A2/pt
Priority to CN2011102142130A priority patent/CN102327267A/zh
Priority to PCT/GB2006/004320 priority patent/WO2007060402A1/en
Priority to CA002628917A priority patent/CA2628917A1/en
Priority to US12/094,702 priority patent/US20090028943A1/en
Priority to AU2006318946A priority patent/AU2006318946A1/en
Priority to EP06808603A priority patent/EP1954247A1/en
Priority to CN200680043657XA priority patent/CN101312715B/zh
Priority to RU2008125197/15A priority patent/RU2008125197A/ru
Priority to UY29952A priority patent/UY29952A1/es
Priority to ARP060105180A priority patent/AR057928A1/es
Priority to NO20082097A priority patent/NO20082097L/no
Priority to ZA200804103A priority patent/ZA200804103B/xx
Priority to EC2008008555A priority patent/ECSP088555A/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0523810.0A 2005-11-23 2005-11-23 Pharmaceutical compositions Ceased GB0523810D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB0523810.0A GB0523810D0 (en) 2005-11-23 2005-11-23 Pharmaceutical compositions
TW095142644A TW200735875A (en) 2005-11-23 2006-11-17 Pharmaceutical compositions
RU2008125197/15A RU2008125197A (ru) 2005-11-23 2006-11-21 Фармацевтические композиции
CA002628917A CA2628917A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions
EP06808603A EP1954247A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions
JP2008541808A JP2009516726A (ja) 2005-11-23 2006-11-21 医薬組成物
BRPI0618906-7A BRPI0618906A2 (pt) 2005-11-23 2006-11-21 composiÇço farmacÊutica e processo para a fabricaÇço de uma composiÇço farmacÊutica
CN2011102142130A CN102327267A (zh) 2005-11-23 2006-11-21 药物组合物
PCT/GB2006/004320 WO2007060402A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions
EP10182729A EP2283828A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions
US12/094,702 US20090028943A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions
AU2006318946A AU2006318946A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions
KR1020087013620A KR20080070056A (ko) 2005-11-23 2006-11-21 약학적 조성물
CN200680043657XA CN101312715B (zh) 2005-11-23 2006-11-21 药物组合物
UY29952A UY29952A1 (es) 2005-11-23 2006-11-22 Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso
ARP060105180A AR057928A1 (es) 2005-11-23 2006-11-23 Composiciones farmaeuticas de azd 2171
NO20082097A NO20082097L (no) 2005-11-23 2008-05-06 Farmasoytiske sammensetninger
ZA200804103A ZA200804103B (en) 2005-11-23 2008-05-13 Pharmaceutical compositions
EC2008008555A ECSP088555A (es) 2005-11-23 2008-06-18 Composiciones farmacéuticas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0523810.0A GB0523810D0 (en) 2005-11-23 2005-11-23 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB0523810D0 true GB0523810D0 (en) 2006-01-04

Family

ID=35601030

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0523810.0A Ceased GB0523810D0 (en) 2005-11-23 2005-11-23 Pharmaceutical compositions

Country Status (17)

Country Link
US (1) US20090028943A1 (enExample)
EP (2) EP2283828A1 (enExample)
JP (1) JP2009516726A (enExample)
KR (1) KR20080070056A (enExample)
CN (2) CN102327267A (enExample)
AR (1) AR057928A1 (enExample)
AU (1) AU2006318946A1 (enExample)
BR (1) BRPI0618906A2 (enExample)
CA (1) CA2628917A1 (enExample)
EC (1) ECSP088555A (enExample)
GB (1) GB0523810D0 (enExample)
NO (1) NO20082097L (enExample)
RU (1) RU2008125197A (enExample)
TW (1) TW200735875A (enExample)
UY (1) UY29952A1 (enExample)
WO (1) WO2007060402A1 (enExample)
ZA (1) ZA200804103B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0017548B8 (pt) * 1999-02-10 2023-05-02 Astrazeneca Ab Composto
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
PE20221838A1 (es) * 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
CN115400136B (zh) * 2022-07-22 2023-10-03 江苏亚邦爱普森药业有限公司 一种克拉霉素固体制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
ES2292414T3 (es) * 2000-07-27 2008-03-16 Roquette Freres Granulos a base de almidon y de lactosa.
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
CA2363528A1 (en) * 2001-11-19 2003-05-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immediate release tablet containing naproxen sodium
CN1625555A (zh) * 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
AU2003245313A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
BRPI0618906A2 (pt) 2013-01-08
KR20080070056A (ko) 2008-07-29
CN101312715A (zh) 2008-11-26
AU2006318946A1 (en) 2007-05-31
CA2628917A1 (en) 2007-05-31
ZA200804103B (en) 2009-10-28
UY29952A1 (es) 2007-06-29
TW200735875A (en) 2007-10-01
EP1954247A1 (en) 2008-08-13
RU2008125197A (ru) 2009-12-27
EP2283828A1 (en) 2011-02-16
CN101312715B (zh) 2011-12-14
AR057928A1 (es) 2007-12-26
WO2007060402A1 (en) 2007-05-31
NO20082097L (no) 2008-08-18
CN102327267A (zh) 2012-01-25
US20090028943A1 (en) 2009-01-29
JP2009516726A (ja) 2009-04-23
ECSP088555A (es) 2008-07-30

Similar Documents

Publication Publication Date Title
GB0513692D0 (en) Novel pharmaceutical compositions
IL223545A0 (en) Pharmaceutical compositions
IL179809A0 (en) Pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
IL188352A0 (en) Pharmaceutical compositions
IL186336A0 (en) Pharmaceutical composition
ZA200804103B (en) Pharmaceutical compositions
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
IL192091A0 (en) Pharmaceutical compositions
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0522045D0 (en) Pharmaceutical compositions
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0407351D0 (en) Pharmaceutical compositions
GB0400971D0 (en) Pharmaceutical compositions
ZA200803566B (en) Pharmaceutical compositions
GB0514259D0 (en) Pharmaceutical compositions
GB0422582D0 (en) Pharmaceutical compositions
GB0411502D0 (en) Pharmaceutical compositions
GB0525269D0 (en) Pharmaceutical compositions
GB0515306D0 (en) Pharmaceutical compositions
GB0513693D0 (en) Novel pharmaceutical compositions
GB0513440D0 (en) Novel pharmaceutical compositions
GB0505693D0 (en) Novel pharmaceutical compositions
GB0512202D0 (en) Novel pharmaceutical compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)